CongenItal Naevus Cohort for Longitudinal Evaluation

Launched by NANTES UNIVERSITY HOSPITAL · Feb 11, 2025

Keywords

ClinConnect Summary

This clinical trial, called the CongenItal Naevus Cohort for Longitudinal Evaluation, is studying congenital nevi (CN), which are pigmented skin marks present at birth. These marks can grow as a child develops and can vary in size. The trial aims to better understand the potential risks associated with larger CNs, such as neurological disorders and melanoma (a type of skin cancer). It also looks at how having a visible CN can affect a child's social life and the worries that parents may face. The ultimate goal is to create clear guidelines for monitoring and treatment that can improve the health and quality of life for children with CN.

To be eligible for this trial, children must be under 2 years old and have a medium, large, or giant congenital nevus. They also need to have health insurance and their parents must agree to their participation. The study is not yet recruiting participants, but once it begins, families can expect regular check-ups and support as researchers gather important information about managing CN and its effects.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient under 2 years old.
• • Patient with a medium, large, or giant congenital nevus (CN) according to the Krengel classification, either single or multiple.
• • Patient affiliated with social security.
• • Patient whose legal representatives consent to their child's participation in the project.
• Exclusion Criteria:
• • Patient with light brown spots or pigmented lesions not classified as nevi.
• • Patient for whom It is impossible to establish annual follow-up.
• • Patient whose parents do not speak French.